APPLICATION
ANDA090083
TYPE
ANDA
ORIGINAL APPROVAL
2010-10-06
LATEST ACTION
2025-09-09
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
LOSARTAN POTASSIUMPrescription
LOSARTAN POTASSIUM 50MG · TABLET · ORAL
LOSARTAN POTASSIUMPrescription
LOSARTAN POTASSIUM 100MG · TABLET · ORAL
LOSARTAN POTASSIUMPrescription
LOSARTAN POTASSIUM 25MG · TABLET · ORAL
Approval history
2025-09-09Labeling · Supplement 36 · standardAP
2022-07-01Labeling · Supplement 31 · standardAP
2020-10-21Labeling · Supplement 17 · standardAP
2016-06-10Labeling · Supplement 13 · standardAP
2015-07-07Labeling · Supplement 11 · standardAP
2014-09-21Labeling · Supplement 10 · standardAP
2013-06-11Labeling · Supplement 9 · standardAP
2012-12-20Labeling · Supplement 7 · standardAP
2012-12-20Labeling · Supplement 5AP
2012-12-20Labeling · Supplement 3AP
2010-10-22Labeling · Supplement 1AP
2010-10-06OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.